tbuckley/cabot-search huggingface dataset:
Improved outcomes among newly diagnosed patients with <scp>FMS‐like tyrosine kinase 3 internal tandem duplication</scp> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification
Authors: Patrick K. Reville, Koji Sasaki, Hagop M. Kantarjian, Naval G. Daver, Musa Yilmaz, Courtney D. Dinardo, Nicholas J. Short, Gautam Borthakur, Naveen Pemmaraju, Rohtesh S. Mehta, Sherry Pierce, Sergej N. Konoplev, Joseph D. Khoury, Guillermo Garcia‐Manero, Marina Y. Konopleva, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia
Journal: American Journal of Hematology (2022)

Mutations in fms-like tyrosine kinase 3 (FLT3) gene are common genomic alterations in acute myeloid leukemia (AML). FLT3 internal tandem duplication mutations (FLT3-ITD) have consistently been shown to be adversely prognostic, particularly those with high allelic ratio (AR). Current AML treatment strategies, including high dose cytarabine, purine analogs, FLT3 inhibitors (FLT3i), and with or without allogeneic stem cell transplant (SCT) have been shown to improve the outcomes in patients with FLT3 mutations. We analyzed a consecutive cohort of newly diagnosed patients with AML treated at a large academic medical center from January 2012 to January 2020. A total of 1576 patients with a new diagnosis of AML were reviewed. Among these, 1438 (91%) had molecular testing for FLT3 mutations and 21% (304/1438) had an FLT3 mutation, including 17% with an FLT3-ITD mutation. We show that FLT3-ITD high AR with NPM1 wild-type have significantly improved survival compared with other European LeukemiaNet (ELN) adverse risk disease. In multivariable cox proportional hazards model of patients receiving intensive or low-intensity induction regimens, FLT3 mutations did not have prognostic significance. The use of allogeneic SCT in CR1 for patients with FLT3 mutations appears to improve survival, particularly in those with ELN adverse risk disease. Overall, this data highlights the changing prognostic impact of FLT3 mutations in a contemporary era with appropriate use of induction therapy combined with targeted agents and allogenic SCT.
Offline: The generation of ghosts
Authors: Richard Horton
Journal: The Lancet (2021)

What happened to our ambition for a different, better world? One has to go back to World War 2 to find a time when our species faced a catastrophe on the scale of this COVID-19 pandemic. In the early 1940s, there were some observers of the mounting global chaos who recognised a need to create a new world order. In England, two writers stood out, and their far-reaching visions contrast sharply with the surprising lack of aspiration shown by my generation today.
Abstract 17262: Recent Trends in Incidence of Pregnancy Related Acute Myocardial Infarction and Associated Outcomes
Authors: Byomesh Tripathi, Purnima Sharma, Varun Kumar, Shilpkumar Arora, Varunsiri Atti, sopan Lahewala, Abhishek Mishra, Shikha Malhotra, Radha Gopalan, Abhishek Deshmukh
Journal: Circulation (2018)

Introduction: Acute myocardial infarction (AMI) during pregnancy is a rare but fatal complication. Recent trends in incidence of pregnancy-related AMI and associated outcomes are unclear. Methods: Nationwide inpatient sample (NIS) database was utilized for years 2005-2014. International classification of disease-Ninth revision (ICD-9) was used to identify pregnancy-related (antepartum as well as postpartum) admissions and acute myocardial infarction (AMI). The primary outcome was incidence and trend of AMI related to pregnancy during the study period. Secondary outcomes were trends in mortality and resource utilization. P-values for trends were generated by Cochrane-Armitage test for categorical variables and simple linear regression for continuous variables. Results: We identified a total of 43,437,621 pregnancy-related hospitalization and 3,786 cases of AMI (86% antepartum and 14% post-partum) were noted during the study period. The incidence of AMI during the study period was 8.7 per 100,000 pregnancies with an overall increase in incidence during study period (relative increase of 18.9%, p &lt;0.001) and concomitant decrease in mortality (relative decrease of 40.05%, p &lt;0.001), cost of care (relative decrease of 8.70%, p&lt;0.001) and length of stay (relative decrease of 13.53%, p&lt;0.001). Conclusions: Incidence of AMI during the period is on the rise in recent years with concomitant improvement in mortality and resource utilization. This reflects improved diagnostic capability and a better understanding of non-atherosclerotic mechanisms of AMI during pregnancy such as spontaneous coronary artery dissection, coronary spasm, and coronary thrombus.
Cholin as a Possible Suprarenal Hormone.—
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AMA Task Force on Physician Workforce Planning
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer
Authors: Fang Yuan, Mengnan Sun, Zhengsheng Liu, Huiqin Liu, Weijian Kong, Rui Wang, Feng Qian
Journal: Theranostics (2022)

Background: Pancreatic cancer comprises not only cancer cells but also a collection of cross-talking noncancerous cells within tumor.Therefore, selective delivery of cytotoxic agents towards cancer cells and limiting the collateral damage to tumor suppressive benign cells, such as effector lymphocytes in the tumor microenvironment, is of great value.Methods: Pancreatic cancer cells harbor oncogenic KRAS which induces a constitutively high level of macropinocytosis.Inspired by such uniquity, we sought to explore the targeting potential of dextran, a biomaterial presumed to be endocytosed in the macropinocytosis dependent manner.Cell entry preference, mechanism and subcellular sorting of dextran with different molecular weights were firstly examined.Triptolide (TP), a potent cytotoxin was then set as the model payload for dextran conjugation.KRAS selectivity and the therapeutic effects of dextran-conjugated TP were investigated via both in vitro cellular studies and in vivo tumor model assessment.Results: Dextran, with a specific molecular weight of 70 kDa rather than other weights, was identified as a robust KRAS-responsive intracellular delivery carrier with enhanced entry upon KRAS mutation.The 70 kDa dextran-conjugated TP (DEX-TP) displayed greater efficacy and cellular deposition efficiency towards KRAS mutant cells than KRAS wild-type cells.Treatment with DEX-TP suppressed tumor progression in KRAS mutant pancreatic cancer orthotopic mouse models with reduced toxicity and significantly extended mouse survival time.Furthermore, the conjugate attained a more favorable therapeutic outcome in the tumor immune microenvironment than the free drug, preserving the fraction of T cells and their effector cytokines.Conclusions: In summary, macropinocytic dextran was able to provide drug delivery selectivity towards KRAS mutant cancer cells and reduce tumor immunity depletion caused by the cytotoxic drug in pancreatic cancer.
California Work-Hour Legislation Fails
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COVID-19: a stress test for trust in science
Authors: None The Lancet
Journal: The Lancet (2020)

Peer Review Week is the annual celebration of the importance of peer review, running Sept 21–25. The theme this year is trust in peer review, a particularly appropriate focus during the COVID-19 pandemic. Trust in research and its role in political decision making and policy changes have never been more at the forefront of public discussion and scrutiny than during the current public health crisis. But what is everyone's role in strengthening this trust?
Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML
Authors: Gabrielle Paras, Linde M. Morsink, Megan Othus, Filippo Milano, Brenda M. Sandmaier, Lucas C. Zarling, Raffaele Palmieri, Gary Schoch, Chris Davis, Marie Bleakley, Mary E. D. Flowers, H. Joachim Deeg, Frederick R. Appelbaum, Rainer Storb, Roland B. Walter
Journal: Blood (2022)
Renal Trauma
Authors: Charles K. Jenkins
Journal: JAMA (1968)

Dr. Kook Sang Oh: This is the first Massachusetts General Hospital admission of a 17-year-old white boy who had been in excellent health until four hours prior to admission when he was kicked in the left flank and developed severe flank pain, nausea, vomiting, and gross hematuria. Physical examination showed nothing unusual except for tenseness in the left upper quadrant without re bound tenderness. Vital signs were within normal limits. Hematocrit reading was 41%, and urinalysis showed microscopic hematuria. Roentgenograms of the chest and abdomen were obtained upon admission. <h3>Discussion</h3> Dr. Laurence L. Robbins: Dr. Weber, what do you think is going on? Dr. Alfred L. Weber: The roentgenogram of the chest shows no evidence of rib fracture, mediastinal widening, pleural effusion, or atelectasis. The lung fields are clear. The roentgenogram of the abdomen shows a slightly dilated transverse colon and several small-bowel loops in the midabdomen and right flank.
Platelet GPIIIa PLA polymorphism and incident cardiovascular disease: The Framingham heart study DaLi Feng, Martin G. Larson, Klaus Lindpaintner, Christopher J. O'Donnell, Murray Mittleman, Izabella Lipinska, Ralph B. D'Agostino, Daniel Levy, Geoffrey H. Tofler. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Journal: Journal of the American College of Cardiology (2001)
Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension
Authors: Nabham Rai, Akylbek Sydykov, Baktybek Kojonazarov, Jochen Wilhelm, Grégoire Manaud, Swathi Veeroju, Clemens Ruppert, Frédéric Perros, Hossein Ardeschir Ghofrani, Norbert Weissmann, Werner Seeger, Ralph T. Schermuly, Tatyana Novoyatleva
Journal: European Respiratory Journal (2022)

Pulmonary arterial hypertension (PAH) is a progressive disease characterised by pro-proliferative and anti-apoptotic phenotype in vascular cells, leading to pulmonary vascular remodelling and right heart failure. Peptidyl-prolyl
Viral hepatitis
Authors: M Yamashiki, A Nishimura, K Takase, T Nakano, Y Kosaka, K Bjoro1, Z Yun2, H Samdal3, T Haaland4, M Caruso, R Cozzolongo, M Bisceglie, F Negro, C Costa, L Amati, M Pirrelli, V Attino, L Zaffarano, R Martinotti, R Cuppone, O Manghisi, F Rosina
Journal: Gut (1994)

3rd UEGW Oslo 1994 A49 92 patients from 17 to 68 with chronic persistent hepatitis (CPH), chronic active hepatitis (CAH), cirrhosis (C), and "reactive" hepatitis (RH) were stud- ied.Levels of PGE, its synthesis in the microsomal fractions and the liver homogenates, along with PGE2 degradation rate in the hepatic tissue were tested.PGE levels in the liver specimen from patients with CAH, CPH and RH did not differ significantly.The patients with active C had significantly lower PGE levels than those having benign chronic hepatitis (CH).The microsomal synthesis of PGE in the patients with CPH, CAH, and C was considerably higher than in the RH cases, while the tissue homogenates from the patients with HC synthesized decreased amounts of PGE.In vitro hepatic degradation level of PGE2 did not differ in the CH patients, and was sharply increased in the C patients (in comparison to CPH and RH).PGE levels and its synthesis by the microsomal fractions and the tissue homogenates were the lowest in the patients with B-virus CH, while PGE2 in vitro degradation rate in those patients was the highest (in the presence of viral replication, confirmed by HBsAg and DNA-polymerase).The relative decrease of PGE formation in the tissue homogenates of pa- tients with C, along with the increase in its microsomal synthesis, characterizes the enhanced PGs incorporation in membrane phospholipids.Low levels of PGE in the hepatic tissue of active C patients are probably due to high rates of its degradation.The factors, which accompany B-virus hepatitis reproduc- tion in liver tissue, can notably impact PGE metabolism, resulting in its lower levels and altering cytoprotection.
The role of the nervous system in rhinitis
Journal: Journal of Allergy and Clinical Immunology (2006)

Learning objectives: ''The role of the nervous system in rhinitis'' 1.To understand how the complex nervous system in the nose mediates responses via sympathetic, parasympathetic, and sensory pathways.2. To describe some of the key substances involved in neural-mediated nasal responses.3. To understand studies of nasal responsiveness in allergic rhinitis and nonallergic rhinitis and how the lower airway may also be involved in nasal reflexes.
Ultimate miniaturization of intravascular ultrasound transducer: Feasibility of a novel guide-wire type catheter (Terumo) Kenichi Ito, Masakazu Yamagishi, Tetsu Yamaguchi, Hatsue Ishibashi-Ueda, Chikao Yutani, Hiroyuki Yagami. National Cardiovascular Center, Suita, Japan, Terumo Corporation, Tokyo, Japan
Journal: Journal of the American College of Cardiology (2001)
Reply to K. Beiske et al
Authors: Elizabeth Sokol, Ami V. Desai, Mark A. Applebaum, Dominique Valteau-Couanet, Julie R. Park, Andrew D.J. Pearson, Gudrun Schleiermacher, Meredith S. Irwin, Michael Hogarty, Arlene Naranjo, Samuel Volchenboum, Susan L. Cohn, Wendy B. London
Journal: Journal of Clinical Oncology (2020)
LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer: Erratum
Authors: Biao Zheng, Jianhua Qu, Kenoki Ohuchida, Haimin Feng, Stephen Jun Fei Chong, Zilong Yan, Yicui Piao, Peng Liu, Nan Sheng, Daiki Eguchi, Takao Ohtsuka, Kazuhiro Mizumoto, Zhong Liu, Shazib Pervaiz, Peng Gong, Masafumi Nakamura
Journal: Theranostics (2021)

[This corrects the article DOI: 10.7150/thno.47001.].
Abstract 17051: Neurocognitive Disorders on Long-Term Follow up of Congenital Heart Disease Patients Undergoing Procedures in Childhood
Authors: Lee H Sterling, Aihua Liu, Liming Guo, Ariane J Marelli
Journal: Circulation (2018)

Introduction: Neurocognitive disorders (NCD) are a growing concern in congenital heart disease (CHD) patients. We hypothesized that early life cardiopulmonary bypass (CBP) as well as age at intervention (AAI) were risk factors for NCDs on long-term follow-up in CHD patients. Methods: Data source was the Quebec CHD database. We defined NCD based on ICD 9 and 10 codes including autism spectrum disorder, global developmental disorder, specific developmental disorder, attention deficit hyperactive disorder, intellectual disability or specific learning deficit. We compared NCD risk from 1983-2010 in 3 cohorts of patients undergoing procedures in childhood: percutaneous atrial septal defect (ASD) closure (no CBP group), surgical ASD closure (short CBP group), and complex CHD lesion repair surgeries (long CBP group). Patients were followed from intervention until NCD diagnosis, death, or administrative censoring whichever came first. Results: By 27 years of follow-up, the cumulative risk of NCD was significantly higher in the complex surgery group compared to the ASD surgery group (crude, 24.9% and 13.4%; p&lt;0.0001) and with adjustments for AAI and sex (Cox regression, p=0.043). By 12 years of follow-up, the cumulative risk of NCD was significantly higher in the complex surgery group compared to the other two groups where the risk was almost identical. Cox models with different follow-up lengths identified younger AAI and male sex being significantly associated with increased risk in NCD. Conclusions: In long-term follow-up of CHD patients, younger AAI of CBP and male sex were associated with increased risk of NCD. Our findings suggest that CBP duration in a wide range of CHD lesions and cohort effects are important predictors of NCD. &lt;!--EndFragment--&gt;
SOCIETY PROCEEDINGS.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Do treatments for psoriasis increase the risk of hospital admission or death caused by COVID-19 infections?
Journal: British Journal of Dermatology (2022)

Abstract Linked Article: Penso et al. Br J Dermatol 2022; 186:59–68. One of the difficult dilemmas facing doctors treating patients with psoriasis during the COVID-19 pandemic has been whether to continue treatments for the disease that potentially may reduce the patient’s resistance to infection. In this study from France the investigating team compared the risk (chance) of admissions to hospital and death among patients with psoriasis receiving different types of treatment for psoriasis compared with patients with psoriasis who were not receiving treatment. The medications studied included topically applied medicines (i.e. ones applied to the skin), oral medicines and biologic medicines; in both of these last groups the medications are designed to reduce some aspects of the immune response. The team used information from patients with psoriasis registered in the French national health data system, which is a database that covers the entire population of France (67 million people). They reviewed data from two time periods covering different waves of the COVID-19 pandemic in France, 15 February to 30 June 2020 and 1 October 2020 to 31 January 2021. They used information from 1.3 million patients with psoriasis; over the first study period, 3871 patients were admitted to hospital with COVID-19 and 759 (20%) died and during the second period 3603 were admitted to hospital with COVID-19 and 686 (19%) died. Although the use of topical and non-biologic treatments in the first period and any treatment in the second period was associated with an increased risk of being admitted to hospital, there was no increased risk of death in any of the treated groups in either period. These results suggest that systemic treatments for patients with psoriasis should be continued during the pandemic. Linked Article: Penso et al. Br J Dermatol 2022; 186:59–68.